Olmesartan/Amlodipin/Hct Viatris (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan/Amlodipine/HCT, is an angiotensin II receptor blocker presented as a tablet for oral use. It is combined with amlodipine, a calcium‑channel blocker, and hydrochlorothiazide, a thiazide‑type diuretic, to treat hypertension in adult patients.

GNH USA supplies Olmesartan/Amlodipine/HCT as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine/HCT is indicated for the management of hypertension, acting on the renin‑angiotensin system, calcium channels and renal sodium handling. - Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with fluid retention: adds diuretic action to control volume overload. - Hypertension requiring combination therapy: provides synergistic blood‑pressure control when monotherapy is insufficient.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: warm sensation and reddening of skin. - Fatigue: general tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Renal impairment: worsening kidney function. - Electrolyte imbalance: hyper‑ or hyponatremia, hyperkalemia. - Hepatic dysfunction: elevated liver enzymes. - Pancreatitis: abdominal pain with nausea.

Careful assessment and monitoring are required when using this combination. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: check serum creatinine and eGFR before and during therapy. - Electrolyte surveillance: monitor sodium, potassium and uric acid levels. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy and lactation: avoid unless clearly needed; discuss risks with a healthcare professional. - Concomitant NSAIDs: may reduce antihypertensive effect and affect renal function. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipine/HCT can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - NSAIDs: may blunt antihypertensive response and impair renal function. - Cyclosporine: increases serum concentrations of olmesartan. - Aliskiren: combined renin‑angiotensin blockade can cause renal dysfunction. - Lithium: increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering effect. - ACE inhibitors: potential for renal impairment and hyperkalemia. - Antidiabetic agents: enhanced hypoglycaemic effect. - Antacids (aluminum/magnesium): may affect absorption of olmesartan. - CYP3A4 inhibitors (e.g., ketoconazole): raise amlodipine concentrations.